Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges
Инновационные стратегии формулирования для биосимиляров: тенденции, фокусированные на системах без буфера, безопасности, регуляторной согласованности и проблемах интеллектуальной собственности
2025-06-17
SCID: 54.1/nnc6sma3
Discuss with AI
AI-based in silico simulationsProcess-Analytical-Technology (PAT)Quality-by-Design (QbD)buffer-free high-concentration systemsintellectual property challengespatent thicketsprotein self-bufferingregulatory flexibility (FDA and EMA)
Figures from the paper
Abstract (AI)
The formulation of biosimilar products critically determines their stability, safety, immunogenicity, and market accessibility. This article presents a novel integrative framework for biosimilar formulation that balances scientific, regulatory, and intellectual property dimensions, offering a holistic perspective rarely unified in the literature. It highlights the growing trend toward buffer-free, high-concentration systems that leverage protein self-buffering to improve patient comfort and formulation stability. The article also addresses regulatory flexibility from the FDA and EMA, which allows scientifically justified deviations from reference formulations to ensure pharmaceutical equivalence and minimize immunogenicity. A novelty of this article is its comprehensive analysis of how digital innovations, such as Quality-by-Design, Process-Analytical-Technology, and AI-based in silico simulations, are transforming formulation design and bioprocess optimization to reduce immunogenic risks and enhance bioequivalence. Two important key takeaways emerge: (1) strategic innovation in formulation, especially using buffer-free and high concentration systems, improve product stability and patient tolerability while complying with regulatory standards; and (2) intellectual property challenges, including patent thickets, strongly influence formulation decisions, making early legal-strategic alignment essential for market entry. The article confirms that practical recommendations for the selection of recombinant therapeutic protein formulations can effectively guide developers and regulators toward safer, more efficient, and commercially viable biosimilar products.
Key Findings
1
Biosimilar formulation critically affects stability, safety, immunogenicity, and market accessibility.
2
Digital innovations (Quality-by-Design, Process-Analytical-Technology, AI-based in silico simulations) transform formulation design and bioprocess optimization to reduce immunogenic risks and enhance bioequivalence.
3
Intellectual property challenges, including patent thickets, strongly influence formulation decisions, necessitating early legal-strategic alignment for market entry.
4
Practical recommendations for selecting recombinant therapeutic protein formulations can guide developers and regulators toward safer, more efficient, and commercially viable biosimilars.
5
Regulatory agencies (FDA and EMA) show flexibility allowing scientifically justified deviations from reference formulations to ensure pharmaceutical equivalence and minimize immunogenicity.
6
Strategic innovation in formulation combined with regulatory compliance enables improved product stability and patient tolerability.
7
Trend toward buffer-free, high-concentration systems leveraging protein self-buffering improves patient comfort and formulation stability.
Research Object
Formulation strategies for biosimilar recombinant therapeutic protein products
Research Subject
Impact of buffer-free, high-concentration systems and integrative design (including safety, stability, immunogenicity, regulatory alignment, digital QbD/PAT/AI tools, and intellectual property constraints) on product stability, patient tolerability, bioequivalence, and market access
Publication Details
Publication Date
2025-06-17
Journal
Publisher
ISSN
Cited by
33
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai7
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews2021
A Comprehensive Survey on Graph Neural Networks2020
Which academic search systems are suitable for systematic reviews or meta‐analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources2019
Machine learning and deep learning based predictive quality in manufacturing: a systematic review2022
Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?2019
Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–192024
Engineering protein glycosylation in CHO cells to be highly similar to murine host cells2023